TY - JOUR T1:短效β< >2-激动剂在哮喘中过度使用与加重风险增加和死亡率相关:全国性的队列研究的全球萨拜娜项目JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01872 -2019欧元SP - 1901872 AU Nwaru明亮。非盟-埃克斯特龙,马格努斯盟——Hasvold Pal盟的功能——但弗雷德里克•AU - Telg Gunilla AU -詹森,过度使用短效β2激动剂(SABA)可能提示哮喘控制不良和不良健康结果。关于沙巴(过度)使用对哮喘加重和死亡率的影响、危险因素和当前基于人群的数据很少，促使全球沙巴(沙巴用于哮喘)规划的启动。方法将来自瑞典国家登记册的数据联系起来，纳入2006-2014年年龄12-45岁、使用≥2种阻塞性肺疾病药物的哮喘患者。沙巴过度使用定义为在纳入后的一年基线期内收集2个沙巴罐。SABA的使用分为3-5、6-10和11+罐/基准年。使用Cox回归来研究SABA的使用与病情加重(住院和/或OCS索赔)和死亡率之间的关系。结果365324例哮喘患者(平均年龄27.6岁;55%的女性)，平均随访85.4个月。大约30%的人过度使用沙巴，其中21%的人收集3-5罐，7%的人收集6-10罐，2%的人收集11+罐。沙巴罐收集数量的增加与加重风险的增加相关:3-5 (HR 1.26; [95% CI] 1.24–1.28); 6–10 (1.44; 1.41–1.46); and 11+ canisters (1.77; 1.72–1.83) compared to ≤2 canisters·year−1. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed): 3–5 (HR 1.26; 95% CI 1.14–1.39); 6–10 (1.67; 1.49–1.87); and 11+ canisters (2.35, 2.02–2.72) compared to ≤2 canisters·year−1.Conclusion One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr Nwaru reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Ekström reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Hasvold reports other from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Telg reports personal fees from Employed by AZ, during the conduct of the study.Conflict of interest: Dr Christer Janson[AQ2] Conflict of interest: Dr Wicklund reports other from Statisticon/AstraZeneca, during the conduct of the study. ER -